RAPP
HealthcareRapport Therapeutics, Inc. Common Stock
Key Drivers
- Strong Liquidity
- No Revenue
- Rising Losses
AIAI Summary
RAPP should now be viewed less as a funding-risk biotech and more as a well-capitalized, catalyst-driven story: its ~$436M cash runway removes near-term dilution pressure, so the stock's upside or downside will be dictated primarily by RAP-219 phase 3 execution and the October bipolar mania readout, with any disappointment likely to trigger a sharp re-rating despite solid solvency.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •No Revenue
- •Rising Losses
RAPP has a very strong cash-rich, minimally levered balance sheet, but zero revenue, persistent losses, and shrinking book value make the investment case highly speculative.
Price Behavior
Key Price Behavior Insights:
- •Higher-highs trend
- •Near resistance
- •Fast rally risk
RAPP has trended higher over the last month with higher highs and higher lows, but after a fast climb into $48.82 it may pause or pull back briefly unless it breaks resistance.
Sharp rebound from the low $40s into the upper $40s suggests stretched short-term momentum
Sentiment & News
Key News Insights:
- •Analyst Upgrade
- •Pipeline Progress
- •Cash Runway
Rapport Therapeutics has a generally positive setup, with a Moderate Buy rating, advancing RAP-219 clinical milestones, and $436.1M in cash expected to fund operations into 2029.
The news is supportive for the stock, as late-stage execution and a strong balance sheet improve visibility and reduce funding risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings